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The overall clinical cardiac regeneration experience suggests that stem cell therapy can be safely performed, but it also
underlines the need for reproducible results for their effective use in a real-world scenario. One of the significant
challenges is the identification and selection of the best suited stem cell type for regeneration therapy. Bone marrow
mononuclear cells, bone marrow-derived mesenchymal stem cells, resident or endogenous cardiac stem cells,
endothelial progenitor cells and induced pluripotent stem cells are some of the stem cell types which have been
extensively tested for their ability to regenerate the lost myocardium. While most of these cell types are being
evaluated in clinical trials for their safety and efficacy, results show significant heterogeneity in terms of efficacy. The
enthusiasm surrounding regenerative medicine in the heart has been dampened by the reports of poor survival,
proliferation, engraftment, and differentiation of the transplanted cells. Therefore, the primary challenge is to create
clearcut evidence on what actually drives the improvement of cardiac function after the administration of stem cells. In this
review, we provide an overview of different types of stem cells currently being considered for cardiac regeneration and
discuss why associated factors such as practicality and difficulty in cell collection should also be considered when selecting
the stem cells for transplantation. Next, we discuss how the experimental variables (type of disease, marker-based selection
and use of different isolation techniques) can influence the study outcome. Finally, we provide an outline of the molecular
and genetic approaches to increase the functional ability of stem cells before and after transplantation.Introduction
An estimated 17 million people each year die of cardiovas-
cular diseases, particularly heart attacks and strokes. In
addition, cardiovascular diseases are also a cause of lifelong
disabilities and a reduction in the productive years of life.
The most common form of heart disease is ischaemic heart
disease (IHD), where there is an imbalance between myocar-
dial oxygen supply and its demand. This often leads to dis-
turbances in impulse formation and conduction in the heart
in the form of arrhythmias and, if the ischaemia is sustained,
necrosis of the heart muscle (myocardial infarction (MI))
may develop [1].
The innate response of the heart to an ischaemic insult
has a deleterious as well as a protective effect. An acute re-
sponse involves the synthesis of inflammatory mediators,
cytokines such as tumour necrosis factor-α, monocyte
chemo-attractant protein-1, and interleukin (IL)-1β, IL-6,
and IL-8 and the up-regulation of cell adhesion molecules* Correspondence: rajesh.katare@otago.ac.nz
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unless otherwise stated.such as E-selectin, intercellular adhesion molecule-1, and
vascular cell adhesion molecule-1. This is followed by an
invasion of monocytes, leukocytes, and macrophages at
the site of injury (Figure 1) [2,3]. There is also an accumu-
lation of dead tissue, metabolites, and cellular debris. Ul-
timately, a necrotic zone is formed in the heart, which, in
due course, leads to functional abnormalities, such as re-
duced myocardial contractility and diastolic dysfunction.
Eventually, the surviving myocardium hypertrophies and
myofibroblasts infiltrate the injury site.
The adaptive response of the heart to this ischaemic in-
sult is the activation of pathways that increase oxygen de-
livery and promote pro-survival responses. This is made
possible by the increased expression of proteins such as
erythropoietin, vascular endothelial growth factor, insulin-
like growth factor 2, and glucose transporter [2]. Neovas-
cularisation occurs in an effort to resupply the ischaemic
zones with blood and is initiated by the release of soluble
stromal cell-derived factor-1 (SDF-1), which is a ligand for
C-X-C chemokine receptor type 4 (CXCR4), a receptor on
many endothelial progenitor cells (EPCs) [4].tral. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Inflammatory response in the heart during ischaemia. ICAM-1, intercellular adhesion molecule-1; IL, interleukin; MCP-1, monocyte
chemo-attractant protein-1; VCAM-1, vascular cell adhesion molecule-1.
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of IHD necessitates a therapy which mimics and magnifies
the heart’s endogenous protective response. Currently, the
standard treatment for people with IHD is surgical interven-
tion with primary angioplasty and/or the introduction of a
stent or a coronary artery bypass graft (CABG). The use of
primary angioplasty and stents to reopen the blocked artery
has resulted in a 33% reduction in the mortality rate in
patients with IHD. Besides surgical procedures, pharmaco-
logical treatments such as coronary vasodilators, anti-
coagulants, and anti-platelet agents also delay the onset of
heart failure [5]. However, pharmacological and surgical
therapies cannot make up for the loss of myocytes. The
only standard therapy for heart failure that addresses the
fundamental problem of cardiomyocyte loss is cardiac
transplantation, but organ transplantation is not always a
feasible option as the number of patients with end-stage
cardiac failure is far greater than actual availability of suit-
able donors [6].
The ongoing experiments and clinical trials conducted to
test the regenerative potential of stem cells in the past de-
cades suggest that stem cell therapy can fulfil most of these
demands. Moreover, it provides an all-inclusive approach for
the treatment of IHD and heart failure (Figure 2) [7]. Pre-
liminary efficacy studies indicate that stem cells have the po-
tential to enhance myocardial perfusion and/or contractile
performance in patients with IHD, (a) by transdifferentiation
into cardiomyocytes or vascular cells and (b) through para-
crine effects by secreting growth factors which stimulate the
repair and growth of host cells and the recruitment of en-
dogenous stem cells [8].
Stem cells from different sources in the treatment
of cardiovascular disease
For regenerative therapy, various cell types at different de-
velopmental stages, including embryonic, foetal, and adultcells, have been considered for transplantation into the
heart. Each cell type will be discussed in detail in the fol-
lowing sections.
Human embryonic stem cells
Embryonic stem cells (ESCs) have the capacity to divide
indefinitely and differentiate into any cell type. Although
ESCs are incapable of spontaneous differentiation into car-
diomyocytes, they can be directed to differentiate into car-
diomyocytes or cardiac progenitor cells using various
induction methods [9]. One established advantage of the
use of ESCs is the ability of ESC-derived cardiomyocytes
(ESC-CMs) to electrically integrate with the heart muscle.
In a swine model of an atrioventricular block, transplanted
human ESC-CMs showed electrical coupling and a rever-
sal of the block [10].
One of the initial technical challenges faced in ESC re-
search was the attainment of high purity and a large yield
of differentiated cells belonging to a single lineage type
[11]. Various approaches, such as genetic modification,
specialised culture methods, and treatment with chemical
and biological factors, have been used to enrich, purify,
and select homogeneous and functionally intact popula-
tions of ESC-CMs generated from heterogeneous ESCs
[10,12,13]. Recently Chong and colleagues [14] succeeded
in generating cardiomyocytes from ESCs on a large scale.
These ESC-CMs were able to successfully engraft and re-
pair the injured myocardium in a primate model of myo-
cardial infarction. These results are encouraging, since
only very few cell types have shown efficacy in large ani-
mals. Importantly, ESCs are pluripotent cells, which give
them an advantage over other adult stem cell types with
limited differentiation potential.
Despite the evidence of ESCs’ efficacy in larger animal
models, their clinical use has been hampered by important
limitations, including their genetic instability, potential
Figure 2 Beneficial effect of stem cells in ischaemic heart disease. CSC, cardiac stem cell; CXCR4, C-X-C chemokine receptor type 4; EPC,
endothelial progenitor cell; EPO, erythropoietin; FGF-2, fibroblast growth factor 2; ICAM-1, intercellular adhesion molecule-1; IGF-1, insulin-like
growth factor 1; IL, interleukin; MCP-1, monocyte chemo-attractant protein-1; MMP, matrix metalloproteinase; SDF-1, stromal cell-derived factor-1;
TB4, thymosin beta-4; TMP, transmembrane protease; TNF, tumour necrosis factor; VCAM-1, vascular cell adhesion molecule-1; VEGF, .
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considerations related to the origin of these cells [15]. In
addition, few European nations, for example, have strict
laws prohibiting ‘destructive embryo research’, while fed-
eral laws in the USA permit the use of embryos which
have been discarded after in vitro fertilisation [16].
Skeletal myoblasts
Skeletal myoblasts, also referred to as skeletal muscle
satellite cells, were one of the initial few cell types first
considered for cardiac regeneration [17]. These cells are
a type of progenitor cell with myogenic capacity, and
they are abundantly expressed in the human body. Iso-
lated skeletal myoblasts can be made to proliferate and
expand in vitro. The other advantages of these cells are
their ability to contract and their capacity to withstand
ischaemic insult [18,19].
The evidence of efficacy in animal models facilitated the
use of skeletal myoblasts in clinical trials. Myoblast Autolo-
gous Grafting in Ischemic Cardiomyopathy (MAGIC) wasthe first randomised placebo-controlled study of myoblast
transplantation. However, this study did not demonstrate an
incremental improvement in left ventricular function over
that provided by CABG alone [20]. Later, multiple experi-
ments were aimed towards trans-differentiating these cells
into cardiomyocytes, but none of the attempts were success-
ful, suggesting that skeletal myoblasts are committed to-
wards a skeletal muscle fate [18].
Moreover, myofibres derived from the transplanted skel-
etal myoblasts fail to integrate electromechanically with the
host myocardium due to a lack of adhesion proteins. This
results in the failure to develop the intercalated discs re-
quired for electrical integration between adjacent myofibres.
The excitement around skeletal myoblasts was further re-
duced when clinical studies reported the occurrence of ven-
tricular arrhythmias following transplantation in patients.
Failure to electrically couple these cells with the existing tis-
sue may be a reason for myofibres’ arrhythmogenicity. Gen-
etic modification to introduce the expression of connexin
43, a gap junction protein, was considered as a strategy for
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Fernandes and colleagues [22] found that this modification
was not sufficient to reduce the arrhythmogenic potential of
these cells.
Bone marrow stem cells
The first research on stem cells was conducted on bone
marrow as early as 1950, which found at least two kinds of
stem cells within bone marrow: hematopoietic stem cells
(HSCs) and mesenchymal stem cells (MSCs). The ability
of transplanted bone marrow-derived cells (BMCs) to re-
generate the infarcted myocardium was first shown by
Orlic and colleagues in 2001 [23]. They demonstrated that
HSCs marked by the surface protein c-kit were account-
able for the trans-differentiation of BMCs into mature car-
diomyocytes, smooth muscle cells, and endothelial cells in
a murine model of MI. In support of the above results, in-
jection of isolated c-kit+ cells into the peri-infarct regions
resulted in improved left ventricular function in the in-
farcted heart [23]. However, their claim regarding the abil-
ity of HSCs to transdifferentiate into cardiovascular cells
has been questioned by several other studies [24-27].
Nevertheless, the important outcome was that these cells
showed a significant improvement in cardiac function
after engraftment. Apart from c-kit, many other cell sur-
face markers have also been identified that define popula-
tions enriched for freshly isolated human HSCs, including
the CD133+ and CD34+ hematopoietic cells [28]. Interest-
ingly, c-kit+ HSCs have never been tested clinically, which
is required to truly compare their efficacy with other cell
types. Similar to the c-kit+ cells, CD34+ cells have also
been considered for cardiac regeneration. CD34+ cells are
routinely used clinically to reconstitute the deficient
hematopoietic system after radiation or chemotherapy
[29]. In addition to being a resident population in the bone
marrow, these cells were identified in the peripheral blood
by Körbling and colleagues [30]. Evidence has suggested
that EPCs and differentiated endothelial cells also express
CD34, leading to studies testing the angiogenic capacity of
bone marrow and peripheral blood-derived CD34+ cells.
These cells also showed the ability to differentiate into car-
diomyocytes and smooth muscle, in addition to endothe-
lial cells, after transplantation into an infarcted heart [31].
However, this approach was questioned by Norol and col-
leagues [32], who did not find any cardiac phenotype fol-
lowing transplantation of CD34+ cells into non-human
primates.
Despite these controversial findings, most clinical trials
to date have used total bone marrow mononuclear cells,
which comprise HSCs, MSCs, and monocytes [33]. A re-
view by the Cochrane Heart Group summarised 33 clinical
trials (1,765 patients) on the effectiveness of BMCs for car-
diac regeneration following acute MI and concluded that
while no significant improvement was observed in themortality and morbidity of the patients who received
BMCs, they demonstrated a significant and sustained im-
provement (12 to 61 months follow-up period) in left ven-
tricular ejection fraction (LVEF) [34]. Further, in a recent
meta-analysis (23 clinical trials and 1,255 patients) the
same group concluded that, in addition to the improve-
ment in LVEF, BMCs were also able to improve the mor-
bidity and mortality in patients with chronic IHD and
congestive heart failure [35]. Despite these promising re-
sults, debate continues about whether the therapeutic po-
tential of BMCs in improving left ventricular function
might be attributed mostly to its paracrine effects [36].
The conclusions from the Cochrane Heart Group were
optimistic but caveats included the high degree of hetero-
geneity observed in the results. A recent study utilised
weighted regression and meta-analysis to compare the re-
sults from 49 trials using BMCs for cardiac regeneration
[37]. This analysis identified 600 discrepancies in 133 re-
ports from these trials. Interestingly, the trials with the
highest number of discrepancies also showed the max-
imum increment in LVEF in patients. The studies that
failed to show any benefit from BMCs had the lowest
number of discrepancies [37]. With such differing data
available from clinical trial results, it is extremely difficult
to draw conclusions on the efficacy of BMCs [38].
Mesenchymal stem cells
MSCs have been typically considered as the cells with the
capacity for self-renewal, and differentiate into the mesen-
chymal lineages, including skeletal myoblasts, chondro-
cytes, and adipose tissue [39]. This classical view is now
challenged as they have been shown to differentiate into
neural (non-mesenchymal) tissues as well [39,40]. The
adherent MSC population is shown to express cell surface
markers CD73, CD105, CD29, CD44, and CD90 and lack
CD34 and CD45, which are mainly expressed by HSCs
[41]. Considering that these cells can be isolated from a
variety of tissues, including bone marrow, adipose tissue,
and cord blood, it makes them a more practical option for
regenerative therapy. The second advantage with MSCs is
that they lack major histocompatibility complex II and B7
co-stimulatory molecule expression; hence, they are able
to evade immune responses and have an innate ability to
overcome the rejection. This opens the possibility of non-
autologous transplantation in patients [39,42].
MSCs have been shown to differentiate into cardiomyo-
cytes as well as vascular endothelial cells in vitro [39].
Conversely, experimental evidence suggests that when trans-
planted in vivo, MSCs contribute to neo-vascularisation and
cardiomyocyte protection, mainly through the activation of
paracrine factors. They may persist within the myocardium
in a differentiated state, although substantial evidence for
their ability to attain cardiac cell phenotype in vivo is still
needed [43].
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The cellular differentiation process was once believed to be
an irreversible process. In 2006, however, Takahashi and
Yamanaka [44] successfully induced pluripotency in som-
atic cells through retroviral transduction of several factors
involved in the self-renewal of ESCs. The combination of
transcriptional factors commonly used for cellular repro-
gramming are Krüppel-like factor 4 (Klf-4), sex determin-
ing region Y-box 2 (Sox-2), c-Myc or octamer-binding
transcription factor 4 (Oct3/4), Nanog, and Lin-28 [44].
Since then, several studies have demonstrated the wide dif-
ferentiation potential of induced pluripotent stem cells
(iPSCs), which includes their ability to differentiate into cell
types from any of the three germ layers [45]. iPSCs have
been found to differentiate into cardiomyocytes, endothe-
lial cells, and smooth muscle cells in vitro. When injected
into the infarcted heart of mice, iPSCs can differentiate
into the cardiac phenotype [46,47].
One of the initial problems with using iPSCs was the
poor experimental efficiency in the successful induction of
pluripotency to somatic cells. The use of genetic factors,
chemical inhibitors, and signalling molecules that can
either replace core reprogramming factors or enhance re-
programming efficiency has now been investigated. Re-
cently, Rais and colleagues [48] found that the Mbd3/
NuRD (nucleosome remodelling and de-acetylation) re-
pressor complex is the predominant molecular block pre-
venting the deterministic induction of ground-state
pluripotency, and hence by depleting the Mbd3 gene, they
could successfully synchronise all cells to attain pluripo-
tency. This does overcome a chief barrier to the clinical
use of iPSCs [48]. Due to their ESC-like properties, how-
ever, they were also found to be tumorigenic [49]. Hence,
to overcome the problem of tumorigenesis, Martens and
colleagues [46] differentiated iPSCs into cardiomyocytes
in vitro before transplanting them into the infarcted heart.
Transplanted cells not only improved the cardiac func-
tions, but also localised to the host myocardium [46]. Fur-
ther, biosynthetic tissues are also created from cardiac cells
derived from iPSCs [50]. Several bioengineering strategies
are being explored to improve the efficacy of iPSC-derived
transplants to improve their engraftment, survival, and
functionality in tissues [51]. The in vivo safety and func-
tionality of these cells need to be assured before their clin-
ical translation is considered.
Endogenous cardiac stem cells
Until a decade ago, most research in cardiology was influ-
enced by the dogma that the heart is a terminally differenti-
ated organ and is incapable of generating new parenchymal
cells. Hence, the only response of cardiomyocytes to stress
was considered to be either hypertrophy or death. However,
evidence has shown that myocytes undergo replication, mi-
totic division, and spontaneous regeneration in the heart[52]. To further discredit the view that the heart is a post-
mitotic organ, research has established the presence of a
pool of resident cardiac progenitor cells and cardiac stem
cells (CSCs) expressing the stem cell surface marker c-kit in
the adult rat (and human) heart [53]. The new dynamic view
considers that cell death and cell restoration in the heart are
a part of organ homeostasis, although the rate of myocyte
renewal/turnover is very low [54]. A cardiac progenitor cell
is an immature but already committed cardiac cell that can
proliferate and mature into precursors which, in turn, de-
velop into one of the main matured cardiac cell types. CSCs
are a heterogenic group of cells and are concentrated in spe-
cific areas of the heart, such as the atria or pericardium [54].
Other populations of stem cells found in the heart are side
population cells (which are identified based on their ability
to exclude Hoechst dye), stem cell antigen-1, and islet-1
transcription factor expressing cells [55,56]. In addition,
CSCs have also been demonstrated to express MSC markers
such as CD90 and CD105 and ESC markers Rex1, Nanog
and Sox2 [57]. Apart from this, CSCs have also been identi-
fied based on the expression of early cardiogenesis markers
such as platelet derived growth factor receptor-α, and foetal
liver kinase-1 [58].
Cardiac stem cell research is a rapidly emerging research
area with many stem cell-like populations being newly dis-
covered in the heart. For example, a recent study indicated
a significant contribution of embryonic epicardial progeni-
tor cells to the cardiomyocyte lineage [59]. Due to the lack
of clearly defined markers, epicardial derived cells have
not been tested rigorously for their therapeutic efficacy, al-
though recent characterisation of these cells based on the
specific marker Wilms tumour-1 could lay the foundation
to further studies [60].
Similarly, a population of adult epicardial-resident car-
diac colony-forming unit fibroblasts isolated by Chong
and colleagues [61] displayed broad trans-germ layer po-
tency in vitro and in vivo. This is a promising cell type
because, unlike the discovery of c-kit-positive cells,
rigorous gene expression and fate lineage analysis was
used to characterise this population. Epicardial-derived
cells might hold the true potential for cardiac regener-
ation owing to their role in embryonic cardiogenesis and
multiple cardiac lineage differentiation capacities. Still, a
deeper dissection of the role of these cells in homeosta-
sis and repair is warranted before they are tested clinic-
ally. Unlike BMCs, for which surface markers have been
extensively characterised, the resident CSCs and cardiac
progenitor cells show a mixed and overlapping expres-
sion of stem cell markers [62].
One of the distinctive features making CSCs a good can-
didate in cardiac regeneration is their cardiac commitment
and ability to undergo consistent cardiomyogenic and an-
giogenic differentiation. CSCs from small sized human
myocardial biopsies can be clonally expanded up to many
Dixit and Katare Stem Cell Research & Therapy  (2015) 6:26 Page 6 of 12fold in vitro [53,63]. CSCs may be preferable over cells
from other lineages (like BMCs) as they have been shown
to reach functional competence and obtain the structural
characteristics of mature myocytes and vessels faster than
BMCs [64].
Many animal studies have documented the ability of
clonally expanded CSCs to improve heart function follow-
ing transplantation in animal models of MI [65]. The bulk
of pre-clinical studies conducted present substantial proof
of clonally expanded CSCs’ regenerative ability and have
paved the way for clinical trials. Stem Cell Infusion in
Patients with Ischemic Cardiomyopathy (SCIPIO) is an
ongoing first-in-human, randomised, open-label trial of
autologous c-kit+ CSCs in patients with heart failure due
to IHD undergoing CABG. The initial data obtained from
this trial looked encouraging and compared favourably
with prior studies on intracoronary bone marrow mono-
nuclear cell infusion in a similar patient population
[66,67]. However, the Lancet (which published the SCIPIO
trial results) has expressed concern over the integrity of
certain data published in the SCIPIO trial, although the
issue remains under review and should not be pre-judged
prior to completion of the investigation [68].
In the CArdiosphere-Derived aUtologous stem CElls to
reverse ventricUlar dySfunction (CADUCEUS) study, 31 pa-
tients with acute MI who had undergone successful coron-
ary angioplasty but were left with reduced cardiac function
were randomised to receive standard care or autologous
cardiosphere-derived cells (CDCs) [69]. CDCs are a natural
mixture of stromal, mesenchymal, and progenitor cells and
are derived from the culture of percutaneous endomyocar-
dial biopsies, which yield spherical multicellular clusters
called ‘cardiospheres’. From these cardiospheres, millions of
proliferative cells that express markers of stromal, mesen-
chymal, and progenitor cell-related antigens, as well as other
cells undergoing spontaneous cardiac differentiation, could
be harvested [70]. The patients treated with CDCs showed a
reduction in scar mass, increased viable heart mass and im-
proved regional contractility [69].
The clinical trials accomplished two crucial goals. Firstly,
they indicated the possibility of culturing therapeutic doses
of autologous CSCs from a small amount of myocardial bi-
opsy tissue. Secondly, these cells could be successfully ad-
ministered by intracoronary injection to patients with prior
MI [67,69,71]. For autologous transplantations, CSCs are
usually isolated from atrial appendages and ventricular and
epicardial biopsies [72]. However, since atrial and ventricu-
lar cardiomyocytes have differential gene expression and
functional efficacy, it is not known whether the stem cells
from atria and ventricles have the same characteristics and
functions [73].
While many of the preclinical and clinical trials, includ-
ing the above mentioned SCIPIO trial, used c-kit+ cells as
the primary source of myocardial regeneration after injury,van Berlo and colleagues [74] recently showed that cardio-
myocytes generated by c-kit+ cells in vivo are functionally
insignificant. In contrast, they demonstrated an ample in-
crease in the number of cardiac endothelial cells by c-kit+
cells. These new findings tempt to speculate that the modest
improvements seen in the heart with these cells in the clin-
ical trial are due to the ability of c-kit+ stem cells to cause
the growth of capillaries, which improves vascularisation, ra-
ther than the generation of new cardiomyocytes [74].
While all the available evidence demonstrates the het-
erogeneity of the CSC population, one important ques-
tion remaining to be addressed is whether the distinct
classes of CSCs have inherently distinct roles in cardiac
regeneration.
Challenges in identifying the best source of stem
cells for cardiac regeneration
The overall clinical cardiac regeneration experience sug-
gests that stem cell therapy can be safely performed. How-
ever, it also suggests that stem cells can be effectively used
only when there are reproducible results, indicating that it
is very important to select the right type of stem cell in
the right clinical setting. Hence, before translation of stem
cell use from preclinical studies to the clinic, one signifi-
cant challenge is the identification and selection of the
best suited stem/progenitor cell types (Figure 3). The pri-
mary task is to obtain clear evidence on what truly drives
the improvement in heart function after the administra-
tion of stem cells. The mechanism(s) underlying the ob-
served functional improvement in the heart remains
unclear and is an issue for debate. Classically, it is believed
that an ideal stem cell should differentiate into cardiomyo-
cytes that integrate both mechanically and electrically with
innate myocytes and should be able to form blood vessels
to boost the blood supply to the scar zone. On the other
hand, recent studies suggest that paracrine factors se-
creted by the stem cells may play a more important role in
the improvement of cardiac function [75]. This has chan-
ged the belief that the stem cells must differentiate into
cardiac cell types to improve cardiac function. Hence,
stem cell types which are not multi-potent themselves can
still improve cardiac function comparable to stem cells
committed to cardiac lineages [76]. The next step now is
to systematically characterise these cells by their ability to
differentiate into cardiac cell types and their ability to im-
prove cardiac health by paracrine mechanisms [8].
Practical and technical challenges
Stem cell source
Many of the cell types considered are pluripotent. The
stem cells that are committed to the myocardial lineage
can be selected using different reporter systems linked to
the endogenous activation and expression of cardiogenic
or myogenic genes. For cardiac regeneration, it is essential
Figure 3 Challenges in stem cell delivery. iPSC, induced pluripotent stem cell; MI, myocardial infarction.
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genic potential, since the injection of highly proliferative
uncommitted pluripotent stem cells can lead to carcino-
genicity. Due to the large amount of heterogeneity in the
number and quality of adult stem cells in patient tissue
samples, selecting and isolating a pure population of car-
diac lineage committed stem cells is essential for the safety
as well as efficacy of stem cell therapy [77].
The number and efficacy of stem cells have been shown
to change depending on several factors such as age, gen-
der, treatments, and pre-existing conditions. Sanada and
colleagues [78] reported a marked decline in the c-kit+
population with an increase in age. This was supported by
another study showing a loss of cardio-protective effects
in CSCs isolated from older patients, which also achievedearly senescence during in vitro culture [79]. In addition
to age, CSCs isolated from patients with pre-existing mor-
bidities, such as diabetes and hypertension or end-stage
heart disease, also showed marked differences in gene ex-
pression, cell survival properties, and functional ability
compared with those isolated from healthy individuals
[80,81]. Similarly, mobilisation of CD34+ cells by granulo-
cyte colony stimulating factor (G-CSF) was found to be
completely impaired in diabetic patients, whereas the
levels of CD34+ cells were increased 2.2-fold after mobil-
isation in non-diabetics [82]. However, some important
questions remain unanswered regarding, for example, the
effect of the severity of the disease, the time since the
acute event, and the duration of pre-existing conditions
such as diabetes and hypertension on the number and
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from the same organ source might show functional differ-
ences depending on the location. For example, CSCs
isolated from the atria and the ventricles might have differ-
ential gene expression and functional efficacies similar to
cardiomyocytes from these two regions [73]. Further, gender
differences in the aging process of the human heart might
also occur in terms of differences in CSC quality [83]. This
evidence suggests the need for more research to develop a
personalised evaluation protocol in order to identify optimal
stem cell sources depending on patient need.
Challenges in isolation and expansion of stem cells
The next challenge in translating stem cell therapy from a
preclinical to a clinical setting is the practicality of its use,
such as the ease and efficiency of its isolation and expan-
sion. Peripheral blood samples are easy to collect, al-
though the relative expansion abilities of the EPCs from
the peripheral blood are limited [80]. In contrast, endo-
myocardial biopsies are difficult to obtain, but CSCs can
be isolated and expanded from tiny (approximately 5 mg)
endomyocardial biopsies [84]. Within the heart, CSCs
from a particular location may be more effective (CSCs
from ventricular biopsies) in myocardial regeneration but
can be difficult to procure.
Another tricky task in stem cell therapy is marker-based
selection. Selection of the right marker for isolation is a
critical decision because of the heterogeneity in stem cells
such as CSCs [85]. In addition, stem cells from the same
source can express heterogeneous markers. Some stem
cell markers represent a ‘moving target’, which means that
cells retain stem cell-like properties even after losing the
expression of these markers following subsequent passages
in culture. Hence, capturing stem cells based on these
markers becomes illusive at times [86]. As above, the se-
verity of the disease, associated pre-existing conditions,
and age also change the expression of stem cell surface
markers and the overall number of stem cells expressing a
particular marker. For example, the percentage of c-kit+
cells was found to be higher in patients with end-stage
heart failure compared with patients without end-stage
heart failure, whereas the number of circulating endothe-
lial progenitor cells was found to decrease with age
[87,88]. The percentage of c-kit was found to be very low
in unfractionated CDCs, while almost 90% of these cells
were found to be positive for MSC markers [57]. While
the suitability of c-kit to identify CSCs has been ques-
tioned, the above evidence implies that a single marker
may not be sufficient for identifying an effective cell popu-
lation [74]. This is further supported by a study from Li
and colleagues [64], who demonstrated the superior effect
of unsorted CDCs compared with a purified c-kit subpop-
ulation. Further studies are required to understand the
best marker(s).In addition to source and marker, isolation technique and
culture conditions also offer a major challenge in the expan-
sion of stem cells. Studies suggest that differences in the in-
tensity of enzymatic digestion may affect the type of cells
isolated [89]. Different cell types, growth conditions, passa-
ging methods, and number of cell passages considered also
influence the outcomes. Pfister and colleagues attributed the
low expression of c-kit in CDCs to enzymatic cleavage dur-
ing the digestion process, as treatment of c-kit+ bone mar-
row cells with a cardiac digestion regimen resulted in a
significant reduction in c-kit+ cells [90]. One other study
showed that CD34+ HSCs undergo epigenetic changes in-
volving DNA methylation, which leads to the loss of stem-
ness over subsequent in vitro culture passages [91].
The need for increased numbers of appropriate cells
continues to limit the clinical development of cell therapy.
This has led to a considerable number of studies focussing
on ex vivo stem cell expansion. Different strategies have
been used for the ex vivo expansion of stem cells from dif-
ferent sources. A high degree of logistic support may be
required for the large scale expansion of stem cells. Open-
system configurations such as culture dishes and flasks
and closed-systems such as gas-permeable bags, stirred/
spinner flasks, flatbed perfusion bioreactors, and three-
dimensional scaffolds have been used for culturing and
expanding stem cells on a large scale [92]. Amplification
of a cell’s proliferation potential is also required. For ex-
ample, HSCs can be expanded ex vivo with the use of spe-
cific growth factors and a serum-free media. Some of
these factors include thrombopoietin, stem cell factor, G-
CSF, IL-6, and Fms-related tyrosine kinase 3 ligand [93].
EPCs are expanded by culturing them on fibronectin in
the presence of growth factors favouring endothelial cell
growth [94]. Fibroblast growth factors have been used for
expanding MSCs and CSCs [65].
The use of growth factors and favourable culture condi-
tions to expand stem cells may also have an effect on their
functional properties [95,96]. Reports suggest that the use
of basic fibroblast growth factor to culture MSCs can ex-
tend the doublings of these cells up to 80 population dou-
blings [96,97]. But as the cells reach senescence, there is a
down-regulation of growth factor receptors, and hence
they may become resistant to the proliferation stimuli
[98,99]. While different combinations of growth factors
have been used to improve the proliferation and functional
efficacy of stem cells, due to the effect of cell culture
conditions on cell physiology it is difficult to compare and
interpret the results from these studies [100].
Stem cell preconditioning strategies
‘Preconditioning’ refers to any pharmacological, envir-
onmental or genetic modification of the cells for the
amplification of their potency. Preconditioning pro-
motes stem cell survival and may promote proliferation,
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in vitro and in vivo [101].
While several studies, including ours, have exclusively
confirmed the differentiation and proliferative ability of
stem cells in in vitro settings, these effects are barely seen
after transplantation in vivo, with less than 3% of injected
cells surviving 1 week after transplantation [102]. To over-
come this challenge, combinations of molecular ap-
proaches, such as chemical and hypoxic preconditioning
and genetic engineering, have been used in an attempt to
boost the ability of transplanted cells to withstand the ad-
verse microenvironment, thereby improving their regen-
erative capacity in vivo [47].
Some of the preconditioning techniques include exposing
the stem cells to hypoxia, treatment with growth factors and
anti-aging compounds, irradiation, and modification of the
cells using microRNAs [79,101]. We recently showed that
transplanted human pericyte progenitor cells repair the
infarcted heart through the activation of an angiogenic
programme involving miR-132 [103]. Hence, targeting the
expression of microRNAs can be a novel possible approach
for enhancing the angiogenic potential of stem cells. Most of
these approaches are aimed at salvaging depleted stem cell
function. In one of these studies, preconditioning of diabetic
MSCs with cardiomyocyte conditioned medium markedly
improved their efficacy after transplantation into the diabetic
heart [104]. In another study, exposing MSCs to SDF-1
significantly enhanced cell survival, proliferation, and en-
graftment of the transplanted cells into the infarcted myo-
cardium via SDF-1/CXCR4 signalling [105]. Of note, most
of the autologous transplantations are performed in elderly
patients with pre-existing diseases; as described above, the
functional efficacy of stem cells in these cases are often im-
paired. Hence, a cell rejuvenation strategy in the form of
preconditioning might be required to salvage the therapeutic
potential of these cells [80]. In support of this notion, stem
cell factor was recently shown to reverse the senescence of
cardiac stem cells in the aging myocardium [78].
Data from individual studies aimed at modulating a sin-
gle target protein or a set of target proteins within a stem
cell are inadequate to select the perfect preconditioning
strategy. There is thus a need for a high throughput
screening plan that can be utilised to identify the whole
array of pro-survival and angiogenic target proteins which
can be used as targets for stem cell preconditioning.
Stem cell delivery to the patient
Finally, when it comes to the delivery of stem cells to a pa-
tient, three important factors need to be considered: first
is the type and nature of the injury, second the timing of
the therapy, and third the ability of the cells to engraft to
the host myocardium.
The decision to select a particular cell type should be in-
fluenced mainly by the nature of the injury. For example, incases of chronic ischaemia with a functional myocardium,
the purpose is to rescue the non-necrotic ischaemic myocar-
dium and improve the blood supply to it. Hence, it is desir-
able to use a cell type that secretes pro-angiogenic factors,
such as BMCs, or cells that induce vascular regeneration,
such as EPCs. On the other hand, if the goal is to regenerate
an infarcted myocardium with severe loss of functional myo-
cardial tissue, it would be more suitable to use a progenitor
cell type, such as CSCs with cardiomyogenic and vasculo-
genic capability, or consider the delivery of functional
ESC-CMs or iPSC-derived cardiomyocytes [106].
As in other cases, a huge dilemma still remains regarding
the best time for stem cell delivery to patients. A compari-
son of two large clinical trials (LateTIME and Reinfusion of
Enriched Progenitor Cells and Infarct Remodelling in Acute
Myocardial Infarction (REPAIR-AMI)) in which patients
underwent intracoronary infusion of BMCs either 3 to 5 days
(REPAIR-AMI) or 2 to 3 weeks (LateTIME) after an acute
event showed significant enhancement of LVEF only in pa-
tients who received BMCs within 5 days after the acute
event [107,108]. This suggests that cell therapy may be effi-
cacious only if administered early after acute MI, which is
impossible in the case of autologous transplantation using
CSCs. However, the SCIPIO and CADUCEUS trials have
demonstrated benefits in patients even when cell therapy
was initiated 4 months and 2 to 4 weeks, respectively, after
an acute event, although it is not clear if this benefit over-
weighs the benefit of the REPAIR-AMI trial [66,69]. The re-
searchers who designed the SCIPIO trial argue that cell
therapy was initiated after 4 months to separate the effects
of CSCs from those of surgical revascularisation immedi-
ately after therapy, as in many patients LVEF is known to
improve spontaneously during the first few months after
CABG surgery [109]. However, due to the lack of immune
reactions with CSCs, they can be embraced as an off-the-
shelf product if future studies confirm that an early time
point could be ideal for stem cell transplantation [110].
In addition to choosing the best stem cell type and the
best timing for the treatment, the most important factor
after transplantation is the ability of the cells to engraft into
the host myocardium. Several studies have reported that cel-
lular engraftment after transplantation into damaged tissues
is inadequate and that transplanted cells are susceptible to
the hostile ischaemic environment and tend to disappear
within a few days [111]. As discussed above, several ongoing
research studies have used different methods to precondi-
tion stem cells prior to transplantation in order to increase
their potential to withstand the adverse microenvironment
following transplantation, with the aim of improving their
engraftment and survival.
Direct cell delivery into the myocardium has been
shown to have disadvantages in terms of meagre cell en-
graftment and poor mechano-electrical coupling. Cardiac
regeneration approaches are evolving from cell therapy to
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an alternative strategy in which cell transplantation is ac-
companied by the support of biomaterials (called scaf-
folds) and regulatory factors (for example, growth factors)
[112]. The in vitro engineering of beating cardiomyocyte-
containing tissue constructs and the engineering of stem
cell-containing tissue constructs are the two strategies
currently used for cell implantation. The cardiac tissue
constructs are formed by seeding cardiomyocytes in
three-dimensional scaffolds and culturing under appropri-
ate conditions to develop cell alignment, electrical com-
munication, and spontaneous beating in vitro [113]. Apart
from using the tissue constructs of beating cardiomyo-
cytes, as indicated above, engineered stem cell sheets are
also an attractive choice for therapeutic delivery, owing to
their paracrine effects and plasticity [114]. In the future,
these bio-engineered cardiac patches or cell sheets may
become the preferred approach for delivering stem cells
into the diseased heart [51,115].
Conclusion
While stem cell therapy has the potential to become a next-
generation treatment, several hurdles need to be overcome
before it becomes a routine therapy for cardiovascular re-
generation. In order to achieve this, it is necessary to design
studies that can systematically compare different cell types
at the same time point with minimal variability in type of
disease, age, gender, and pre-existing conditions.
Abbreviations
BMC: Bone marrow-derived cell; CABG: Coronary artery bypass graft;
CADUCEUS: CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar
dySfunction; CDC: Cardiosphere-derived cell; CSC: Cardiac stem cell; CXCR4: C-X-C
chemokine receptor type 4; EPC: Endothelial progenitor cell; ESC: Embryonic stem
cell; ESC-CM: ESC-derived cardiomyocyte; G-CSF: Granulocyte colony stimulating
factor; HSC: Hematopoietic stem cell; IHD: Ischaemic heart disease; IL: Interleukin;
iPSC: Induced pluripotent stem cell; LVEF: Left ventricular ejection fraction;
MI: Myocardial infarction; MSC: Mesenchymal stem cell; REPAIR-AMI: Reinfusion of
enriched progenitor cells and infarct remodelling in acute myocardial infarction;
SCIPIO: Stem cell Infusion in patients with Ischemic Cardiomyopathy; SDF-1: Stromal
cell-derived factor-1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PD performed extensive literature search and wrote the first draft of the
manuscript. RK designed the manuscript, performed literature search and
drafted the manuscript. Both authors read and approved the final
manuscript.
Acknowledgements
This study was supported by research project grants from Lottery
Health Board, New Zealand Society for the Study of Diabetes, JC
Anderson Trust and Heart Foundation New Zealand (grant number
1600). PD is a doctoral student supported by the University of Otago
Doctoral Scholarship.References
1. Effat MA. Pathophysiology of ischemic heart disease: an overview.
AACN Clin Issues. 1995;6:369–74.
2. Chi NC, Karliner JS. Molecular determinants of responses to myocardial
ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock
factors. Cardiovasc Res. 2004;61:437–47.
3. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res.
2008;58:88–111.
4. Ghadge SK, Muhlstedt S, Ozcelik C, Bader M. SDF-1alpha as a therapeutic
stem cell homing factor in myocardial infarction. Pharmacol Therapeut.
2011;129:97–108.
5. Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, et al.
Clinical effectiveness and cost-effectiveness of immediate angioplasty for
acute myocardial infarction: systematic review and economic evaluation.
Health Technol Assess. 2005;9:1–99.
6. Evans RW. Socioeconomic aspects of heart transplantation. Curr Opin
Cardiol. 1995;10:169–79.
7. Segers VF, Lee RT. Stem-cell therapy for cardiac disease.
Nature. 2008;451:937–42.
8. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell
signaling and therapy. Circ Res. 2008;103:1204–19.
9. Manuilova ES, Gordeeva OF, Grivennikov IA, Ozernyuk ND. Embryonic stem cells:
spontaneous and directed differentiation. Biol Bull Russ Acad Sci. 2001;28:595–600.
10. Li R, Xue T, Cho H, Akar F, Tsang S, Jones S, et al. Functional integration of
electrically active cardiac derivatives from genetically engineered human
embryonic stem cells with quiescent recipient ventricular cardiomyocytes:
insights into the development of cell-based pacemakers. Circulation.
2005;111:11–20.
11. Chen A, Ting S, Seow J, Reuveny S, Oh S. Considerations in designing
systems for large scale production of human cardiomyocytes from
pluripotent stem cells. Stem Cell Res Ther. 2014;5:12–2.
12. Bernstein HS. Cardiac repair and restoration using human embryonic stem
cells. Regen Med. 2012;7:697.
13. He W, Ye L, Li S, Liu H, Wang Q, Fu X, et al. Stirred suspension culture
improves embryoid body formation and cardiogenic differentiation of
genetically modified embryonic stem cells. Biol Pharmaceut Bull.
2012;35:308–16.
14. Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, et al. Human
embryonic-stem-cell-derived cardiomyocytes regenerate non-human
primate hearts. Nature. 2014;510:273–7.
15. Robertson JA. Human embryonic stem cell research: ethical and legal issues.
Nat Rev Genet. 2001;2:74–8.
16. Dhar D, Hsi-en HJ. Stem cell research policies around the world. Yale J Biol
Med. 2009;82:113–5.
17. Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chiu RC. Cell transplantation for
myocardial repair: an experimental approach. Cell Transplant. 1992;1:383–90.
18. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not
transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell
Cardiol. 2002;34:241–9.
19. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, et al.
Autologous skeletal myoblasts transplanted to ischemia-damaged
myocardium in humans. Histological analysis of cell survival and
differentiation. J Am Coll Cardiol. 2003;41:879–88.
20. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart
L, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy
(MAGIC) trial: first randomized placebo-controlled study of myoblast
transplantation. Circulation. 2008;117:1189–200.
21. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, et al.
Engraftment of connexin 43-expressing cells prevents post-infarct
arrhythmia. Nature. 2007;450:819–24.
22. Fernandes S, Rijen HVMV, Forest V, Evain S, Leblond A, Mérot J, et al. Cardiac
cell therapy: overexpression of connexin43 in skeletal myoblasts and
prevention of ventricular arrhythmias. J Cell Mol Med. 2009;13:3703–12.
23. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson S, Li B, et al. Bone
marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–5.
24. Murry C, Soonpaa M, Reinecke H, Nakajima H, Rubart M, Pasumarthi K, et al.
Haematopoietic stem cells do not transdifferentiate into cardiac myocytes
in myocardial infarcts. Nature. 2004;428:664–8.
25. Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be
mobilized and differentiate into cardiomyocytes after myocardial infarction
in mice. Kidney Int. 2005;68:1940–3.
Dixit and Katare Stem Cell Research & Therapy  (2015) 6:26 Page 11 of 1226. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, et al. Bone
marrow-derived hematopoietic cells generate cardiomyocytes at a low
frequency through cell fusion, but not transdifferentiation. Nat Med.
2004;10:494–501.
27. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC.
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic
myocardium. Nature. 2004;428:668–73.
28. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al.
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood. 1997;90:5002–12.
29. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review:
Evidence for CD34 as a common marker for diverse progenitors. Stem Cells.
2014;32:1380–9.
30. Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, et al.
Hepatocytes and epithelial cells of donor origin in recipients of
peripheral-blood stem cells. N Engl J Med. 2002;346:738–46.
31. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z.
Transdifferentiation of human peripheral blood CD34 + −enriched cell
population into cardiomyocytes, endothelial cells, and smooth muscle cells
in vivo. Circulation. 2003;108:2070–3.
32. Norol F, Bonnet N, Peinnequin A, Chretien F, Legrand R, Isnard R, et al.
GFP-transduced CD34+ and Lin- CD34- hematopoietic stem cells did not
adopt a cardiac phenotype in a nonhuman primate model of myocardial
infarct. Exp Hematol. 2007;35:653–61.
33. Arnous S, Mozid A, Martin J, Mathur A. Bone marrow mononuclear cells and
acute myocardial infarction. Stem Cell Res Ther. 2012;3:2.
34. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, et al. Stem
cell treatment for acute myocardial infarction. Cochrane Database Syst Rev.
2012;2:Cd006536.
35. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E.
Stem cell therapy for chronic ischaemic heart disease and congestive heart
failure. Cochrane Database Syst Rev. 2014;4:CD007888.
36. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left
ventricular remodelling of ischemic heart through paracrine signalling.
Circ Res. 2006;98:1414–21.
37. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi H-M, Shun-Shin MJ, Jones
S, et al. Discrepancies in autologous bone marrow stem cell trials and
enhancement of ejection fraction (DAMASCENE): weighted regression and
meta-analysis. BMJ. 2014;348:g2688.
38. Abbott A. Doubts over heart stem-cell therapy. Nature. 2014;509:15–6.
39. Pittenger MF. Multilineage potential of adult human mesenchymal stem
cells. Science. 1999;284:143–7.
40. Long X, Olszewski M, Huang W, Kletzel M. Neural cell differentiation in vitro
from adult human bone marrow mesenchymal stem cells. Stem Cells Dev.
2005;14:65–9.
41. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al.
Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8:315–7.
42. Kuraitis D, Ruel M, Suuronen EJ. Mesenchymal stem cells for cardiovascular
regeneration. Cardiovasc Drugs Ther. 2011;25:349–62.
43. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al.
Monolayered mesenchymal stem cells repair scarred myocardium after
myocardial infarction. Nat Med. 2006;12:459–65.
44. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors.
Cell. 2006;126:663–76.
45. Lee J-H, Lee JB, Shapovalova Z, Fiebig-Comyn A, Mitchell RR, Laronde S, et al.
Somatic transcriptome priming gates lineage-specific differentiation potential
of human-induced pluripotent stem cell states. Nat Commun. 2014;5:5605.
46. Martens A, Kensah G, Rojas S, Rotärmel A, Baraki H, Haverich A, et al. Induced
pluripotent stem cell (iPSC)-derived cardiomyocytes engraft and improve heart
function in a mouse model of acute myocardial infarction. Thorac Cardiovasc
Surg. 2012;60:PP26.
47. Yu SP, Wei Z, Wei L. Preconditioning strategy in stem cell transplantation
therapy. Transl Stroke Res. 2013;4:76–88.
48. Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, et al. Deterministic
direct reprogramming of somatic cells to pluripotency. Nature. 2013;502:65–70.
49. Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS.
Induced pluripotency and oncogenic transformation are related processes.
Stem Cells Dev. 2013;22:37–50.50. Christoforou N, Liau B, Chakraborty S, Chellapan M, Bursac N, Leong KW.
Induced pluripotent stem cell-derived cardiac progenitors differentiate to
cardiomyocytes and form biosynthetic tissues. PLoS One. 2013;8:e65963.
51. Fisher MB, Mauck RL. Tissue engineering and regenerative medicine: recent
innovations and the transition to translation. Tissue Eng Part B Rev. 2013;19:1–13.
52. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al.
Evidence that human cardiac myocytes divide after myocardial infarction.
N Engl J Med. 2001;344:1750–7.
53. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al.
Adult cardiac stem cells are multipotent and support myocardial
regeneration. Cell. 2003;114:763–76.
54. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and
regeneration in cardiac hypertrophy and failure. Circ Res. 2003;92:139–50.
55. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult
cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol
Chem. 2004;279:11384–91.
56. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, et al. Postnatal
isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages.
Nature. 2005;433:647–53.
57. Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, et al.
Human cardiac stem cells exhibit mesenchymal features and are
maintained through Akt/GSK-3beta signaling. Biochem Biophys Res
Commun. 2007;352:635–41.
58. Chong JJ, Reinecke H, Iwata M, Torok-Storb B, Stempien-Otero A, Murry CE.
Progenitor cells identified by PDGFR-alpha expression in the developing
and diseased human heart. Stem Cells Dev. 2013;22:1932–43.
59. Singh MK, Epstein JA. Epicardium-derived cardiac mesenchymal stem cells:
expanding the outer limit of heart repair. Circ Res. 2012;110:904–6.
60. Smart N, Bollini S, Dube KN, Vieira JM, Zhou B, Davidson S, et al. De novo
cardiomyocytes from within the activated adult heart after injury. Nature.
2011;474:640–4.
61. Chong JJ, Chandrakanthan V, Xaymardan M, Asli NS, Li J, Ahmed I, et al.
Adult cardiac-resident MSC-like stem cells with a proepicardial origin.
Cell Stem Cell. 2011;9:527–40.
62. Ellison GM, Galuppo V, Vicinanza C, Aquila I, Waring CD, Leone A, et al.
Cardiac stem and progenitor cell identification: different markers for the
same cell? Front Biosci. 2010;2:641–52.
63. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, et al.
Isolation and expansion of adult cardiac stem cells from human and murine
heart. Circ Res. 2004;95:911–21.
64. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, et al. Direct
comparison of different stem cell types and subpopulations reveals superior
paracrine potency and myocardial repair efficacy with cardiosphere-derived
cells. J Am Coll Cardiol. 2012;59:942–53.
65. Barile L, Chimenti I, Gaetani R, Forte E, Miraldi F, Frati G, et al. Cardiac stem
cells: isolation, expansion and experimental use for myocardial regeneration.
Nat Clin Practice Cardiovasc Med. 2007;4:S9–S14.
66. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, et al.
Administration of cardiac stem cells in patients with ischemic cardiomyopathy:
the SCIPIO trial surgical aspects and interim analysis of myocardial function and
viability by magnetic resonance. Circulation. 2012;126:S54–64.
67. Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, et al.
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO):
initial results of a randomised phase 1 trial. Lancet. 2011;378:1847–57.
68. The Lancet Editors. Expression of concern: the SCIPIO trial. Lancet.
2014;383:1279.
69. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al.
Intracoronary cardiosphere-derived cells for heart regeneration after
myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.
Lancet. 2012;379:895–904.
70. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E. Regenerative
potential of cardiosphere-derived cells expanded from percutaneous
endomyocardial biopsy specimens. Circulation. 2007;115:896–908.
71. Oldroyd KG, Berry C, Bartunek J. Myocardial repair and regeneration: bone
marrow or cardiac stem cells? Mol Ther. 2012;20:1102–5.
72. Hsiao L-C. Endogenous cardiac stem cell therapy for ischemic heart failure.
J Clin Exp Cardiol. 2013;S11:007. doi: 10.4172/2155-9880.S11-007.
73. Ng SY, Wong CK, Tsang SY. Differential gene expressions in atrial and
ventricular myocytes: insights into the road of applying embryonic stem
cell-derived cardiomyocytes for future therapies. Am J Physiol Cell Physiol.
2010;299:C1234–49.
Dixit and Katare Stem Cell Research & Therapy  (2015) 6:26 Page 12 of 1274. van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC,
et al. c-kit+ cells minimally contribute cardiomyocytes to the heart.
Nature. 2014;509:337–41.
75. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, et al.
Relative roles of direct regeneration versus paracrine effects of human
cardiosphere-derived cells transplanted into infarcted mice. Circ Res.
2010;106:971–80.
76. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role
in vascular biology. Circ Res. 2004;95:343–53.
77. Kamp TJ. Recognizing heart cells in a crowd. Nat Methods. 2011;8:1013–6.
78. Sanada F, Kim J, Czarna A, Chan NY, Signore S, Ogorek B, et al. c-Kit-positive
cardiac stem cells nested in hypoxic niches are activated by stem cell factor
reversing the aging myopathy. Circ Res. 2014;114:41–55.
79. Avolio E, Gianfranceschi G, Cesselli D, Caragnano A, Athanasakis E, Katare R,
et al. Ex vivo molecular rejuvenation improves the therapeutic activity of
senescent human cardiac stem cells in a mouse model of myocardial
infarction. Stem Cells. 2014;32:2373–85.
80. Itzhaki-Alfia A, Leor J, Raanani E, Sternik L, Spiegelstein D, Netser S, et al.
Patient characteristics and cell source determine the number of isolated
human cardiac progenitor cells. Circulation. 2009;120:2559–66.
81. Seewoodhary J, Evans PJ. Diabetes and stem cells: endogenous effects and
reparative mechanisms. Br J Diabetes Vasc Dis. 2013;13:224–8.
82. Fadini GP, Albiero M, Vigili de Kreutzenberg S, Boscaro E, Cappellari R,
Marescotti M, et al. Diabetes impairs stem cell and proangiogenic cell
mobilization in humans. Diabetes Care. 2013;36:943–9.
83. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, et al.
Gender differences and aging: effects on the human heart. J Am Coll
Cardiol. 1995;26:1068–79.
84. D’Amario D, Fiorini C, Campbell PM, Goichberg P, Sanada F, Zheng H, et al.
Functionally competent cardiac stem cells can be isolated from
endomyocardial biopsies of patients with advanced cardiomyopathies. Circ
Res. 2011;108:857–61.
85. Mishra R, Vijayan K, Colletti EJ, Harrington DA, Matthiesen TS, Simpson D,
et al. Characterization and functionality of cardiac progenitor cells in
congenital heart patients. Circulation. 2011;123:364–73.
86. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical
notes on endothelial progenitor cells: ways to escape from the knowledge
plateau. Atherosclerosis. 2008;197:496–503.
87. Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, et al.
Age-dependent depression in circulating endothelial progenitor cells in
patients undergoing coronary artery bypass grafting. J Am Coll Cardiol.
2003;42:2073–80.
88. Ballard VL, Edelberg JM. Stem cells for cardiovascular repair - the challenges
of the aging heart. J Mol Cell Cardiol. 2008;45:582–92.
89. Leinonen JV, Emanuelov AK, Platt Y, Helman Y, Feinberg Y, Lotan C, et al.
Left atrial appendages from adult hearts contain a reservoir of diverse
cardiac progenitor cells. PLoS One. 2013;8:e59228.
90. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, et al. CD31- but
not CD31+ cardiac side population cells exhibit functional cardiomyogenic
differentiation. Circ Res. 2005;97:52–61.
91. Weidner CI, Walenda T, Lin Q, Wölfler MM, Denecke B, Costa IG, et al.
Hematopoietic stem and progenitor cells acquire distinct DNA-hypermethylation
during in vitro culture. Sci Rep. 2013;3:3372.
92. Madlambayan GJ, Rogers I, Purpura KA, Ito C, Yu M, Kirouac D, et al.
Clinically relevant expansion of hematopoietic stem cells with conserved
function in a single-use, closed-system bioprocess. Biol Blood Marrow
Transplant. 2006;12:1020–30.
93. Douay L. Experimental culture conditions are critical for ex vivo expansion
of hematopoietic cells. J Hematother Stem Cell Res. 2001;10:341–6.
94. Peplow PV. Influence of growth factors and cytokines on angiogenic
function of endothelial progenitor cells: a review of in vitro human studies.
Growth Factors. 2014;32:83–116.
95. Walenda T, Bokermann G, Ventura Ferreira MS, Piroth DM, Hieronymus T,
Neuss S, et al. Synergistic effects of growth factors and mesenchymal
stromal cells for expansion of hematopoietic stem and progenitor cells.
Exp Hematol. 2011;39:617–28.
96. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation
and survival of multipotential stromal cells. Stem Cell Res Ther. 2010;1:32.
97. Yanada S, Ochi M, Kojima K, Sharman P, Yasunaga Y, Hiyama E. Possibility
of selection of chondrogenic progenitor cells by telomere length in
FGF-2-expanded mesenchymal stromal cells. Cell Prolif. 2006;39:575–84.98. Tran KT, Rusu SD, Satish L, Wells A. Aging-related attenuation of EGF
receptor signaling is mediated in part by increased protein tyrosine
phosphatase activity. Exp Cell Res. 2003;289:359–67.
99. Shiraha H, Gupta K, Drabik K, Wells A. Aging fibroblasts present reduced
epidermal growth factor (EGF) responsiveness due to preferential loss of
EGF receptors. J Biol Chem. 2000;275:19343–51.
100. Weidner CI, Walenda T, Lin Q, Wolfler MM, Denecke B, Costa IG, et al.
Hematopoietic stem and progenitor cells acquire distinct DNA-
hypermethylation during in vitro culture. Sci Rep. 2013;3:3372.
101. Mohsin S, Siddiqi S, Collins B, Sussman MA. Empowering adult stem cells for
myocardial regeneration. Circ Res. 2011;109:1415–28.
102. Malliaras K, Marban E. Cardiac cell therapy: where we’ve been, where we
are, and where we should be headed. Br Med Bull. 2011;98:161–85.
103. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, et al.
Transplantation of human pericyte progenitor cells improves the repair of
infarcted heart through activation of an angiogenic program involving
micro-RNA-132. Circ Res. 2011;109:894–906.
104. Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery M, et al.
Preconditioning diabetic mesenchymal stem cells with myogenic medium
increases their ability to repair diabetic heart. Stem Cell Res Ther. 2013;4:1–13.
105. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning
enhances cell survival and differentiation of stem cells during
transplantation in infarcted myocardium. Cardiovasc Res. 2008;77:134–42.
106. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, et al.
Reduction of myocardial infarct size by human mesenchymal stem cell
conditioned medium. Stem Cell Res. 2008;1:129–37.
107. Mills JS, Rao SV. REPAIR-AMI: stem cells for acute myocardial infarction.
Future Cardiol. 2007;3:137–40.
108. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al. Effect
of intracoronary delivery of autologous bone marrow mononuclear cells 2
to 3 weeks following acute myocardial infarction on left ventricular
function: the LateTIME randomized trial. JAMA. 2011;306:2110–9.
109. Shivalkar B, Maes A, Borgers M, Ausma J, Scheys I, Nuyts J, et al. Only
hibernating myocardium invariably shows early recovery after coronary
revascularization. Circulation. 1996;94:308–15.
110. Torella D, Ellison GM, Nadal-Ginard B, Indolfi C. Cardiac stem and progenitor
cell biology for regenerative medicine. Trends Cardiovasc Med. 2005;15:229–36.
111. Cho HJ, Lee HJ, Youn SW, Koh SJ, Won JY, Chung YJ, et al. Secondary
sphere formation enhances the functionality of cardiac progenitor cells.
Mol Ther. 2012;20:1750–66.
112. Le Huu A, Paul A, Xu L, Prakash S, Shum-Tim D. Recent advancements in
tissue engineering for stem cell-based cardiac therapies. Ther Deliv.
2013;4:503–16.
113. Zimmermann W-H, Schneiderbanger K, Schubert P, Didié M, Münzel F,
Heubach JF, et al. Tissue engineering of a differentiated cardiac muscle
construct. Circ Res. 2002;90:223–30.
114. Narita T, Shintani Y, Ikebe C, Kaneko M, Campbell NG, Coppen SR, et al. The
use of scaffold-free cell sheet technique to refine mesenchymal stromal
cell-based therapy for heart failure. Mol Ther. 2013;21:860–7.
115. Zhang G, Hu Q, Braunlin EA, Suggs LJ, Zhang J. Enhancing efficacy of stem
cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue
Eng Part A. 2008;14:1025–36.
